entertainment -WSS

entertainment

author：focus 2025-09-30 22:10:11 - browse：688

Christine Kao/STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves. So when new market developments threaten to diminish or wipe away that revenue stream, PBMs find crafty ways to keep as much of those dollars as possible — often at the expense of employers.

One such case occurred last year, when a wave of Humira biosimilars entered the market and drug companies slashed the list prices of their insulin products. CVS Caremark, the PBM owned by CVS Health that oversees the prescription drug benefits of 103 million people, told its employer clients that it anticipated “more lower-cost products (including specialty biosimilars) may become preferred products” on its lists of approved drugs for 2024, according to documents obtained by STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： FDA panel endorses Alnylam’s heart drug — after picking it apart

focus

WSS

CDC recommends RSV monoclonal antibody for infants

Popular nasal decongestant doesn't actually relieve congestion

CDC recommends RSV monoclonal antibody for infants

Private equity could exacerbate cardiology's overuse problem, experts fear

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

FDA scientists endorse Pfizer/BioNTech Covid

focus

entertainment

focus

Wildfire smoke exposes gaps in outdoor worker protections

How to ethically and practically extend health care to all

Duchenne breakthrough therapy leaves behind pioneering families

Hospitals consider fixing cancer drug shortages on their own

Peter Hotez and the public health issue of online harassment

'Null' research findings aren't empty of meaning. Let's publish them

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

2 officers injured in shooting in Orlando, police say

Apple is now the first public company to be valued at $3 trillion

When waiting feels immoral: Empathy in the emergency department

explore

Acelyrin, a rare IPO success, stumbles in its first big test

How I helped Pfizer think through the ethics of Viagra

Acelyrin, a rare IPO success, stumbles in its first big test

Acelyrin, a rare IPO success, stumbles in its first big test

Generate Biomedicines machine learning biotech raises $273M

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Wikipedia

focus

focus

explore